« Return to News | R&D Trends

International Stem Cell, Duke collaborate on Parkinson's disease

Friday, August 30, 2013 02:22 PM

International Stem Cell (ISCO), a California-based biotechnology company developing novel stem cell-based therapies, has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's neural stem cell product.

ISCO's Parkinson's program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. The hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to differentiate into dopaminergic neurons and express neurotrophic factors such as glial derived neurotrophic factor  and brain-derived neurotrophic factor to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's, especially in cases where current dopamine-replacement approaches fail to adequately control the symptoms.

Mark Stacy, M.D., vice dean for clinical research, neurology at Duke University School of Medicine, will be the study's Principal Investigator. The research will be coordinated by the Duke Clinical Research Institute.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.